COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

• DOI: 10.1038/s41375-021-01450-8
• Publication Date: 2021-11-01T12:03:07Z
• Authors: Thomas Chatzikons...; Anargyros Kapetan...; Lydia Scarfò; Georgios Karakats...; David Allsup; Alejandro Alonso ...; Martin Andres; Darko Antic; Mónica Baile; Panagiotis Baliakas; Dominique Bron; Antonella Capasso; Sofia Chatzileont...; Raul Cordoba; Juan-Gonzalo Correa; Carolina Cuéllar-...; Lorenzo De Paoli; Maria Rosaria De ...; Giovanni Del Poeta; Christos Demosthe...; Maria Dimou; David Donaldson; Michael Doubek; Maria Efstathopoulou; Barbara Eichhorst; Shaimaa El-Ashwah; Alicia Enrico; Blanca Espinet; Lucia Farina; Angela Ferrari; Myriam Foglietta; Henrik Frederiksen; Moritz Fürstenau; José A. García-Marco; Rocío García-Serra; Massimo Gentile; Eva Gimeno; Andreas Glenthøj; Maria Gomes da Silva; Odit Gutwein; Yervand K. Hakobyan; Yair Herishanu; José Ángel Hernán...; Tobias Herold; Idanna Innocenti; Gilad Itchaki; Ozren Jaksic; Ann Janssens; Оlga B. Kalashnikova; Elżbieta Kalicińska; Linda Katharina K...; Arnon P. Kater; Sabina Kersting; Jorge Labrador; Deepesh Lad; Luca Laurenti; Mark-David Levin; Enrico Lista; Alberto Lopez-Garcia; Lara Malerba; Roberto Marasca; Monia Marchetti; Juan Marquet; Mattias Mattsson; Francesca R. Mauro; Ivana Milosevic; Fatima Mirás; Marta Morawska; Marina Motta; Talha Munir; Roberta Murru; Carsten U. Niemann; Raquel Nunes Rodr...; Jacopo Olivieri; Lorella Orsucci; Maria Papaioannou; Miguel Arturo Pav...; Inga Piskunova; Viola Maria Popov; Francesca Maria Q...; Giulia Quaresmini; Kristian Qvist; Gianluigi Reda; Gian Matteo Rigolin; Rosa Ruchlemer; Gevorg Saghumyan; Amit Shrestha; Martin Šimkovič; Martin Špaček; Paolo Sportoletti; Oana Stanca; Niki Stavroyianni; Tamar Tadmor; Doreen Te Raa; Sanne H. Tonino; Livio Trentin; Ellen Van Der Spek; Michel van Gelder; Roel van Kampen; Marzia Varettoni; Andrea Visentin; Candida Vitale; Ewa Wasik-Szczepanek; Tomasz Wróbel; Lucrecia Yáñez Sa...; Mohamed Yassin; Marta Coscia; Alessandro Rambaldi; Emili Montserrat; Robin Foà; Antonio Cuneo; Kostas Stamatopoulos; Paolo Ghia
• Keywords: Case fatality rate; Immunosuppression; Hematology

Abstract Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due age, disease, and treatment-related immunosuppression. We aimed assess risk factors of outcome elucidate the impact CLL-directed treatments on course COVID-19. conducted a retrospective, international study, collectively including 941 patients CLL confirmed Data from beginning pandemic until March 16, 2021, were collected 91 centers. The case fatality rate (CFR), severity, overall survival (OS) investigated. OS analysis was restricted severe COVID-19 (definition: hospitalization need oxygen or admission into an intensive care unit). CFR in 38.4%. inferior for all treatment categories compared untreated ( p < 0.001). Untreated had lower death (HR = 0.54, 95% CI:0.41–0.72). higher older those suffering cardiac failure 1.03, CI:1.02–1.04; HR 1.79, CI:1.04–3.07, respectively). Age, treatment, significant OS. better chance than recently treated.